Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06455293 | RECRUITING | Parkinson Disease

Psilocybin Therapy for Depression in Parkinson's Disease
Sponsor:

Joshua Woolley, M.D., PhD

Information provided by (Responsible Party):

Joshua Woolley, M.D., PhD

Brief Summary:

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

Condition or disease

Parkinson Disease

Depression

Intervention/treatment

Psilocybin

Phase

PHASE2

Detailed Description:

This is a randomized controlled trial of oral psilocybin therapy for depression in people with Parkinson's disease (PD). The primary goal is to examine efficacy of psilocybin therapy in this patient population. We will enroll 60 people ages 40 to 80 with clinically diagnosed early to moderate stage Parkinson's disease (Hoehn and Yahr Stage 1-3 during an "on" period), who meet criteria for moderate or greater depression severity and meet all other inclusion and exclusion criteria at screening. Participants will complete two drug administration sessions where they will each receive a dose of oral psilocybin ranging from low ("microdose") to high in a medically monitored setting with psychotherapeutic support. Participants will also complete a series of psychotherapy sessions before and after each drug administration session. Clinical assessments, neuroimaging, non-invasive brain stimulation, and peripheral blood draws will be used to quantify changes in depression, other non-motor and motor symptoms of PD, quality of life, and selected neural and blood-based biomarkers at multiple time points. Follow-up will continue to 3 months after the second session. Primary endpoints will evaluate efficacy, safety, and tolerability of study procedures.

Study Type : INTERVENTIONAL
Estimated Enrollment : 60 participants
Masking : QUADRUPLE
Masking Description : Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) This trial is testing various doses of psilocybin. Participants, study staff and clinical assessors will be blinded to individual treatment conditions until study close-out. The clinician administered instruments will be administered by different clinical study staff than the facilitators who provide the preparation, psilocybin therapy, and integration sessions.
Primary Purpose : TREATMENT
Official Title : The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
Actual Study Start Date : 2024-08-19
Estimated Primary Completion Date : 2027-06
Estimated Study Completion Date : 2028-06

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 40 Years to 80 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Age 40 to 80
  • * Comfortable speaking and writing in English
  • * Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an "on" phase (time when medication/DBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect)
  • * Currently experiencing depressive symptoms
  • * Able to attend all in-person visits at UCSF as well as virtual visits
  • * Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating
Exclusion Criteria
  • * Psychotic symptoms involving loss of insight
  • * Significant cognitive impairment
  • * Regular use of medications that may have problematic interactions with psilocybin
  • * A health condition that makes this study unsafe or unfeasible, determined by study physicians
Psilocybin Therapy for Depression in Parkinson's Disease

Location Details

NCT06455293

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, California

University of California, San Francisco

San Francisco, California, United States, 94143